Form 4 for KURA Kura Oncology, Inc.
Accepted 2025-03-24 00:00:00 ET · period of report 2025-03-21 · accession 0000950170-25-043903 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-24 | 2025-03-21 | KURA | Hasnain Faheem | Dir | M - OptEx | $6.32 | +22.7K | 46.7K | +95% | +$143.4K | |
| 2025-03-24 | 2025-03-21 | KURA | Hasnain Faheem | Dir | S - Sale+OE | $8.00 | -22.7K | 24.0K | -49% | -$181.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-21 | M | A | 22,682 | $6.32 | 46,665 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-21 | S | D | 22,682 | $8.00 | 23,983 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $8.00 to $8.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |